244101-02-8 Usage
Description
N-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide is a complex organic compound characterized by its unique molecular structure. It is a derivative of sulfonyl and naphthalenyl compounds, which may exhibit specific chemical and biological properties due to its distinct arrangement of atoms and functional groups.
Uses
Used in Pharmaceutical Research:
N-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide is used as a research compound for studying its potential interactions with biological targets. The compound's unique structure may allow it to modulate specific receptors or enzymes, making it a candidate for the development of new drugs.
Used in Chemical Synthesis:
N-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide can be utilized as an intermediate in the synthesis of more complex molecules, potentially leading to the creation of novel pharmaceuticals or other specialty chemicals.
Used in Material Science:
Due to its structural characteristics, N-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide may have applications in the development of new materials with specific properties, such as improved stability or reactivity.
Used in Analytical Chemistry:
The compound can be employed as a reference material or standard in analytical chemistry, particularly in the development and validation of new methods for the detection and quantification of similar organic compounds.
Used in the Development of EP3 Receptor Antagonists:
N-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide is used as a selective prostanoid receptor EP3 antagonist for studying prostanoid receptor signaling. It helps in understanding the regulation of COX-2 levels and the central excitatory effects of PGE(2) on PVN neurons, which can be crucial in the development of new treatments for various conditions related to prostanoid receptor activity.
Used in Prostanoid Receptor Signaling Studies:
In the field of prostanoid receptor signaling, N-[(5-Bromo-2-methoxyphenyl)sulfonyl]-3-[2-(2-naphthalenylmethyl)phenyl]-2-propenamide is used to block the actions of sulprostone, an EP3-selective agonist. This application aids in demonstrating the vascular contraction effects of PGE2 due to its prostanoid EP3 agonist activity, which is vital for advancing our understanding of prostanoid receptor roles in physiological and pathological processes.
Biochem/physiol Actions
L-798106 was among the first prostanoid receptor EP3-selective antagonists. It has been used in multiple studies to tease out EP3 agonist activity, both in vitro and in vivo. It successfully blocks the actions of sulprostone, an EP3-selective agonist, and it helped show that the vascular contraction effect of PGE2 is due to its prostanoid EP3 agonist activity.
Check Digit Verification of cas no
The CAS Registry Mumber 244101-02-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,4,4,1,0 and 1 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 244101-02:
(8*2)+(7*4)+(6*4)+(5*1)+(4*0)+(3*1)+(2*0)+(1*2)=78
78 % 10 = 8
So 244101-02-8 is a valid CAS Registry Number.
244101-02-8Relevant articles and documents
Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor
Juteau, Helene,Gareau, Yves,Labelle, Marc,Sturino, Claudio F.,Sawyer, Nicole,Tremblay, Nathalie,Lamontagne, Sonia,Carriere, Marie-Claude,Denis, Danielle,Metters, Kathleen M.
, p. 1977 - 1984 (2007/10/03)
Potent and selective antagonists of the human EP3 receptor have been identified. The structure-activity relationship of the chemical series was conducted and we found several analogues displaying sub-nanomolar Ki values at the EP3 receptor and micromolar activities at the EP1, EP2 and EP4 receptors. The effect of added human serum albumin (HSA) on the binding affinity at the EP3 receptor was also investigated.
